Thermo Fisher Scientific to Acquire Advanced Bioprocessing Business from BD
Thermo Fisher Scientific Inc. has signed a definitive agreement with BD (Becton, Dickinson and Compan), under which Thermo Fisher will acquire BD's Advanced Bioprocessing business. This business combines a strong technical services program with a variety of peptones that enhance cell culture media formulations to improve yield and reduce variability in biopharmaceutical applications.
"Thermo Fisher has a trusted value proposition for customers who are working in biologic drug development and manufacturing," said Mark Stevenson, executive vice president and chief operating officer of Thermo Fisher Scientific. "The addition of these new capabilities will complement our bioproduction offering and strengthen our ability to serve this rapidly growing market, from development to large-scale production."
Patrick Kaltenbach, president of Life Sciences for BD, said "We are excited that our Advanced Bioprocessing team will have the opportunity to join a company with deep expertise and a long-standing commitment to supporting biopharmaceutical production. It will create new prospects, building on a 25-year history of ensuring that high-quality biopharmaceuticals get to the market quickly."
BD's Advanced Bioprocessing business has annualized revenue of approximately $100 million and will be integrated into Thermo Fisher's Life Sciences Solutions Segment.
The transaction is subject to customary closing conditions and is expected to close in early 2019.
Organizations
Other news from the department business & finance
These products might interest you

CHOventure Growth Medium by Capricorn Scientific
High-Yield Protein Production with CHO Cells for Biopharmaceutical Applications
Optimized for High-Density Cultures and Enhanced Protein Yields in CHO Cell Bioprocessing

HEK Media by Sartorius
Serum-free cell culture media for HEK cells
Optimised for HEK293 cells and viral vector production, ISO 9001 certified

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Topic world Cell culture technology
Cell culture technology is a central pillar in biotechnological and pharmaceutical research and development. It enables the growth and maintenance of cells under controlled laboratory conditions, providing a window into the molecular and cellular processes of life.

Topic world Cell culture technology
Cell culture technology is a central pillar in biotechnological and pharmaceutical research and development. It enables the growth and maintenance of cells under controlled laboratory conditions, providing a window into the molecular and cellular processes of life.
Last viewed contents

Holes in T cells - Study reveals previously unknown function of immune cells
Taconic Biosciences and Cellaria Biosciences collaborate to facilitate xenograft use in oncology research

This is how the superbug Pseudomonas aeruginosa reacts to antibiotics - Specific properties might become targets for drugs
Category:Swiss_biochemists
Validation of the dossier for drug approval of Biofrontera's BF-200 ALA successful
All tied up: Tethered protein provides long-sought answer
Naturalpha launches a clinical investigation center for nutrition
Biosignal: Collaboration with international company on agriculture applications - Evaluation for use in crop protection to be conducted over 9 months
Modified_starch
Indivumed to study the integrity of biospecimen sampling procedures for the U.S. National Cancer Institute - Analysis of biopsy sampling procedures a prerequisite for the development of future individualized cancer therapies
